Loading...
Market
Will Pfizer report positive results from dose optimization studies for once-daily Danuglipron by the end of 2024?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Pfizer's official press releases or clinical trial registry updates
Story
Pfizer Advances Development of Once-Daily Weight-Loss Pill Danuglipron with Dose Optimization Studies in 2024
Jul 11, 2024, 12:04 PM
Pfizer Inc has announced plans to advance the development of a once-daily formulation of its experimental obesity pill, danuglipron. The company will conduct dose optimization studies in the second half of 2024 following promising pharmacokinetic results from early-stage trials. This move comes after Pfizer scrapped a twice-daily version of the drug late last year. The reworked once-daily modified release version aims to capture a share of the lucrative multibillion-dollar market for obesity medications. Danuglipron is an oral GLP-1 receptor agonist, a class of drugs known for their efficacy in weight loss. Pfizer's decision to proceed with the once-daily formulation reflects its commitment to addressing obesity, a significant public health issue.
View original story
Similar markets
Yes • 50%
No • 50%
Successful with significant efficacy • 25%
Successful with moderate efficacy • 25%
Unsuccessful due to adverse effects • 25%
Unsuccessful due to lack of efficacy • 25%
First half of 2025 • 25%
Second half of 2025 • 25%
2026 • 25%
2027 or later • 25%
Yes • 50%
No • 50%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
Study inconclusive • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Positive results • 33%
Negative results • 33%
Inconclusive results • 34%